Table 1. Characteristics of studies and AUC analyses.
| ID | Projects | AUC (95% CI) | Normal Samples | Tumor Samples | Cut-off value | FP | FN | TP | TN |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TCGA-LUAD | 0.928 (0.903, 0.952) | 59 | 526 | 0.768746 | 5 | 98 | 428 | 54 |
| 2 | TCGA-BRCA | 0.955 (0.94, 0.969) | 113 | 1104 | 0.882547 | 8 | 139 | 965 | 105 |
| 3 | TCGA-UCEC | 0.787 (0.737, 0.838) | 35 | 548 | 1.070402 | 3 | 195 | 353 | 32 |
| 4 | TCGA-LUSC | 0.985 (0.972, 0.998) | 49 | 501 | 0.846782 | 1 | 20 | 481 | 48 |
| 5 | TCGA-HNSC | 0.876 (0.837, 0.915) | 44 | 502 | 0.971722 | 3 | 137 | 365 | 41 |
| 6 | TCGA-KIRC | 0.912 (0.878, 0.946) | 72 | 535 | 0.573303 | 13 | 58 | 477 | 59 |
| 7 | TCGA-PRAD | 0.712 (0.644, 0.779) | 52 | 499 | 0.689123 | 10 | 235 | 264 | 42 |
| 8 | TCGA-BLCA | 0.905 (0.845, 0.965) | 19 | 411 | 0.828988 | 2 | 60 | 351 | 17 |
| 9 | TCGA-THCA | 0.742 (0.676, 0.809) | 58 | 510 | 0.690223 | 10 | 189 | 321 | 48 |
| 10 | TCGA-KIRP | 0.783 (0.706, 0.859) | 32 | 289 | 0.390211 | 11 | 62 | 227 | 21 |
| 11 | TCGA-LIHC | 0.921 (0.89, 0.952) | 50 | 374 | 0.104429 | 3 | 60 | 314 | 47 |
| 12 | TCGA-STAD | 0.951 (0.918, 0.984) | 32 | 375 | 0.691021 | 6 | 26 | 349 | 26 |
| 13 | TCGA-COAD | 0.941 (0.919, 0.963) | 41 | 471 | 0.943438 | 2 | 74 | 397 | 39 |
| 14 | TCGA-READ | 0.93 (0.889, 0.971) | 10 | 167 | 0.91301 | 0 | 24 | 143 | 10 |
| 15 | TCGA-CHOL | 1 (1, 1) | 9 | 36 | 0.287042 | 0 | 0 | 36 | 9 |
LUAD, lung adenocarcinoma; BRCA, breast carcinoma; UCEC, uterine corpus endometrial carcinoma; LUSC, lung squamous cell carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; PRAD, prostate adenocarcinoma; BLCA, bladder carcinoma; THCA, thyroid carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; STAD, stomach adenocarcinoma; COAD, colon adenocarcinoma; READ, rectum adenocarcinoma; CHOL, cholangiocarcinoma.